Global Cutaneous T-Cell Lymphoma (CTCL) Clinical Landscape Market Report 2021-2031 – ResearchAndMarkets.com

Global Cutaneous T-Cell Lymphoma (CTCL) Clinical Landscape Market Report 2021-2031 – ResearchAndMarkets.com




Global Cutaneous T-Cell Lymphoma (CTCL) Clinical Landscape Market Report 2021-2031 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)” report has been added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the Cutaneous T-Cell Lymphoma (CTCL) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, recent events and analyst opinion, probability of success, a 10-year disease incidence and prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2017, there were approximately 15,200 incident cases of cutaneous T-cell lymphoma (CTCL) worldwide, and forecasts that number to increase to 18,060 incident cases by 2026.

In 2017, there were approximately 5,930 incident cases of CTCL in the US and five major European markets (France, Germany, Italy, Spain, and the UK), which is forecast to increase to 6,160 incident cases by 2026.

The publisher estimates that there were approximately 41,900 10-year prevalent cases of CTCL in the US and five major European markets in 2017, which is expected to increase to 45,030 cases by 2026.

Approved drugs in the CTCL space target antibody-drug conjugate, cluster of differentiation 30, tumor necrosis factor receptor superfamily member 8, microtubules, histone deacetylase, interleukin-2, protein synthesis, chemokine receptor 4, retinoid X receptors, retinoid receptors, DNA, and DNA synthesis. These drugs are administered via the intravenous, topical, and oral routes.

The majority of industry-sponsored drugs in active clinical development for CTCL are in Phase II, with only one drug in Phase III. Therapies in development for CTCL focus on a wide variety of targets. The greatest proportion of pipeline drugs in development are administered intravenously, with the remainder being tested in oral, topical, and intratumoral formulations.

High-impact upcoming events for drugs in the CTCL space comprise topline Phase II trial results for resminostat, AFM13, and IPH4102.

The overall likelihood of approval of a Phase I hematologic asset is 9.2%, and the average probability a drug advances from Phase III is 60%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for CTCL have been in the early and mid-phases of development, with 88% of trials in Phase I-II, and only 12% in Phase III-IV.

The US has a substantial lead in the number of CTCL clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the CTCL space is dominated by completed trials. Bristol Myers Squibb has the highest number of completed clinical trials for CTCL, with six trials. Bristol Myers Squibb also leads the industry sponsors with the highest overall number of clinical trials for CTCL, followed by Merck & Co.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Skin-directed therapy
  • Systemic therapy

EPIDEMIOLOGY

  • Incidence methodology for the US and five major European markets
  • Prevalence methodology for the US and five major European markets

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • SGX301 for CTCL (October 22, 2020)
  • Cobomarsen for CTCL (October 5, 2020)
  • SGX301 for CTCL (April 30, 2020)
  • SGX301 for CTCL (March 19, 2020)
  • Copiktra for CTCL (July 25, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • No English Funding For Lymphoma Drugs Ledaga and Poteligeo

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Kyowa Kirin Bags China Rights To Helsinn’s Chlormethine
  • Curon Picks Up China-Plus Rights to Rhizen’s Tenalisib
  • Almirall Gets Option To Buy Bioniz, Partners With 23andMe

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

Companies Mentioned

  • 23andMe
  • Almirall
  • Curon
  • Helsinn
  • Kyowa Kirin
  • Rhizen

For more information about this report visit https://www.researchandmarkets.com/r/5hs7de

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900